Company profile for Ashvattha Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ashvattha Therapeutics was founded by scientific leaders in nanomedicine and serial entrepreneurs who collectively have founded numerous startups. The founders have raised over >$1B in capital though IPOs, and have advanced therapeutics from IND through to commercial launch. Together, the team is developing dendrimer drug conjugates across a diverse range of therapeutic areas. We are also seeking collaborations with biopharm...
Ashvattha Therapeutics was founded by scientific leaders in nanomedicine and serial entrepreneurs who collectively have founded numerous startups. The founders have raised over >$1B in capital though IPOs, and have advanced therapeutics from IND through to commercial launch. Together, the team is developing dendrimer drug conjugates across a diverse range of therapeutic areas. We are also seeking collaborations with biopharma partners to enable the targeted delivery of their therapeutics.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1235 Radio Road, Suite 200 Redwood City, CA 94065
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/17/3189117/0/en/Ashvattha-Therapeutics-to-Showcase-Topline-Phase-2-Data-and-Recent-FDA-Alignment-at-Upcoming-Investor-and-Ophthalmology-Meetings.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/10/14/3166111/0/en/Ashvattha-Therapeutics-Appoints-Ophthalmology-Veteran-Robert-J-Dempsey-as-Interim-CEO-Following-Positive-Phase-2-Results-and-FDA-Alignment-on-Pivotal-Program.html

GLOBENEWSWIRE
14 Oct 2025

https://www.globenewswire.com/news-release/2025/10/08/3163285/0/en/Ashvattha-Therapeutics-to-Present-Phase-2-DME-and-nAMD-Data-at-Innovate-Retina.html

GLOBENEWSWIRE
08 Oct 2025

https://www.globenewswire.com/news-release/2025/08/26/3139187/0/en/Ashvattha-Therapeutics-to-Present-Late-Breaking-Phase-2-DME-and-nAMD-Data-at-25th-EURETINA-Congress.html

GLOBENEWSWIRE
26 Aug 2025

https://www.globenewswire.com/news-release/2025/06/30/3107454/0/en/Ashvattha-Therapeutics-Presents-Positive-Interim-Phase-2-Results-for-Subcutaneous-Migaldendranib-Treatment-for-DME-and-Wet-AMD-at-2025-MaculArt-Meeting.html

GLOBENEWSWIRE
30 Jun 2025

https://www.globenewswire.com/news-release/2025/06/23/3103349/0/en/Ashvattha-Therapeutics-Reports-the-Ability-to-Tune-Nanomedicines-to-Image-Neuroinflammation-in-Multiple-Sclerosis-Patients-and-Tumor-Associated-Macrophages-in-Cancer-at-SNMMI-Annua.html

GLOBENEWSWIRE
23 Jun 2025

ABOUT THIS PAGE

Contact Ashvattha Therapeutics and get a quotation

Ashvattha Therapeutics is a supplier offers 2 products (APIs, Excipients or Intermediates).

Find a price of 18F-OP-801 bulk with DMF offered by Ashvattha Therapeutics

Find a price of F-OP-801 bulk with DMF offered by Ashvattha Therapeutics

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty